Ben Freeberg
Oncology Ventures Thesis: Early Detection for Breast Cancer
The state of breast cancer early-detection today One out of every eight women we know will be diagnosed with invasive breast cancer in...
top of page
Cancer care is a fragmented industry, ripe with inefficient care delivery, perverse incentives amongst key stakeholders, regulatory hurdles, and a complex, high-cost patient population. There is a growing dichotomy that exists in cancer care in the U.S. between the availability of clinically sound treatment options and the actual delivery of that care.
Oncology Ventures will invest in cancer-focused data, infrastructure, IT and services start-ups as we look to fundamentally change the way cancer care is designed and delivered at scale. Note that our fund will not be investing in drugs, therapeutics or medical devices.
We believe that due to the inherent complexity of oncology and the significant variability that exists amongst cancer cases, even between patients with the same cancer diagnosis, cancer startups deserve a cancer-focused venture fund to help them scale.
OUR ONCOLOGY MARKET THESIS
Cancer spend in the US is $210B, growing at 12% per year
Cancer is the
second-leading cause
of death in the U.S.
of cancer patients lose
their life savings within
two years of diagnosis
42%
new cancer diagnoses each year
1.9 MILLION
Anchor 2
By leveraging a thesis-based approach within oncology, Oncology Ventures will thoughtfully invest across the cancer care continuum.
Our investment themes tackle the core issues in cancer care today, focusing on the parts of the journey with the largest costs and greatest potential opportunity to positively impact care outcomes. We will continue to publish our theses publicly. Three overarching themes are...
01
02
03
Infrastructure, Education and Access
Data Accessibility and Scalability
Scalable Care, Navigation and Support
The opportunity for cost savings
from early cancer detection and
diagnosis is $26B per year
Only half of cancer patients are treated in accordance with evidence-based medicine
1/3 of hospitalizations are preventable during cancer treatment
OUR TEAM
LIMITED PARTNER ADVISORY COMMITTEE
Dr. Harlan Levine
President of Health Innovation and Policy, City of Hope
Harlan is accountable for innovation, product development, and government relations at City of Hope. He previously held executive roles at UnitedHealth Group, Towers Watson and Anthem Inc. He currently serves on advisory boards for numerous healthcare organizations and serves as chairman of the board for AccessHope, a spinout company from City of Hope.
Dr. Nini Wu
Chief Medical and Development Officer of the Navista™ Network, Cardinal Health
We look forward to working with Cardinal Health as they launch Navista™ Network and continue supporting the delivery of patient-centric and value-based care in community oncology.
Prior, Dr. Wu was the Senior VP of Strategic Initiatives at McKesson and President of NY Oncology Hematology.
Dr. Louis Potters
Chair of Radiation Medicine and Deputy Physician-in-Chief,
Northwell Health Cancer Institute
Published 200+ articles and authored national cancer treatment guidelines. Marilyn and Barry Rubenstein Chair in Cancer Research at the Northwell Heath Cancer Institute.
INSIGHTS
bottom of page